PharmacoEconomics

, Volume 12, Issue 3, pp 303–306 | Cite as

The Economic Potential of Tamoxifen Prophylaxis in Breast Cancer

Current Opinion

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: part 1. Lancet 1992; 339(8784): 1–15Google Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: part 2. Lancet 1992; 339(8785): 71–85Google Scholar
  3. 3.
    Plowman PN. Tamoxifen as adjuvant therapy in breast cancer: current status. Drugs 1993; 46(5): 819–33PubMedCrossRefGoogle Scholar
  4. 4.
    Glasziou P, Haas M. An economic evaluation of the use of tamoxifen in the treatment of early breast cancer [unpublished]. Sydney: Centre for Health Economics Research and Evaluation, Westmead Hospital; 1994. Discussion paper no.: 25Google Scholar
  5. 5.
    Corry JF, Lønning PE. Systemic therapy in breast cancer: efficacy and cost-utility. Pharmacoeconomics 1994; 5(3): 198–212PubMedCrossRefGoogle Scholar
  6. 6.
    Love RR. Tamoxifen prophylaxis in breast cancer. Oncology 1992; 6(7): 33–8PubMedGoogle Scholar
  7. 7.
    Meyskens PL, Atiba JO. The Love article reviewed. Oncology 1992; 6(7): 38–9Google Scholar
  8. 8.
    Spicer DV, Henderson BE. The Love article reviewed. Oncology 1992; 6(7): 40–3Google Scholar
  9. 9.
    Bush TL, Helzlsouer KJ. Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol Rev 1993; 15(1): 223–43Google Scholar
  10. 10.
    Chlebowski RT, Butler J, Nelson A, et al. Tamoxifen: current issues and future prospective. Cancer 1993; 72 (3 Suppl.): 1032–7PubMedCrossRefGoogle Scholar
  11. 11.
    Ganz PA, Day R, Ware JE, et al. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 1995; 87(18): 1372–82PubMedCrossRefGoogle Scholar
  12. 12.
    Powles TJ, Tillyer CR, Jones AL. Prevention of breast cancer with tamoxifen: an update on the Royal Marsden Hospital Pilot Programme. Eur J Cancer 1990; 26(6): 680–4PubMedCrossRefGoogle Scholar
  13. 13.
    Costa A. Breast cancer chemoprevention. Eur J Cancer 1993; 29A(4): 589–92PubMedCrossRefGoogle Scholar
  14. 14.
    Costa A. Tamoxifen trial in healthy women at risk of breast cancer [letter]. Lancet 1993; 342: 444PubMedCrossRefGoogle Scholar
  15. 15.
    Nease RF, Ross JM. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. Am J Med 1995; 99: 180–89PubMedCrossRefGoogle Scholar
  16. 16.
    Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151(9): 1842–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.National Centre for Epidemiology and Population HealthThe Australian National UniversityCanberraAustralia

Personalised recommendations